Total Health
M

Best of Bladder Cancer and RCC From ESMO 2023 and GU ASCO 2024

By Total Health FEATURING Melissa Reimers
By Total Health FEATURING Melissa Reimers
413 views
March 5, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

21:09
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam

Featured Video

19:47
Janssen Oncology

All Things PSA

Feat. J. Hamilton, M. Fabrizio, M. Taha

Related Content

AUTOPLAY
16:05
Insights from 2024 ASCO® GU Annual Meeting

Recent GU Developments and Their Clinical Implications

Feat. T. Powles, B. Rini
13:37
SIR 2023 Conference Coverage

SIR 2023: Renal Cell Carcinoma Guidelines - What's New in 2023?

Feat. N. Kothary
17:50
AdventHealth

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Feat. G. Sonpavde
22:19
Insights from 2023 ESMO Annual Meeting

Bladder Cancer Highlights From ESMO 2023: Comparing and Contrasting …

Feat. G. Sonpavde
29:25
Young Chae

Hyperprogression in Cancer Treated With Immunotherapy

14:00
Insights from 2024 ASCO® GU Annual Meeting

ASCO® GU 2024 Summary: "Key Highlights in Bladder/Urothelial Ca…

Feat. G. Sonpavde
07:27
Jason Levy

Opus One: Final Results - RFA in Axial Skeleton

17:32
Kriti Mittal

Current Updates in Urothelial Cancer: Clinical Implications for Prac…

19:41
Balazs Halmos

How I Manage Immune Adverse Events in Solid Tumors

06:01
ecancer

ESMO 2023 Insights: "Phase 3 EV-302 Trial - Evaluating the Comb…

Feat. T. Powles
19:30
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2024

Sequencing 1L Therapies in Metastatic Urothelial Carcinoma

Feat. P. Grivas
30:03
UCSF School of Medicine

Recent Advances in Advanced Urothelial Cancers: Time for a New Stand…

Feat. T. Friedlander
11:29
Oncology Data Advisor

Enfortumab Vedotin + Pembro for Previously Untreated Advanced Urothe…

Feat. T. Powles
13:54
AdventHealth

FDA Approval of Gemcitabine-Cisplatin + Nivo as 1L Therapy for Advan…

Feat. G. Sonpavde
16:19
OncoAlert

Year in Review: RCC Practice Changing and Practice Informing Trials …

Feat. T. Choueiri
07:10
Viktor Grünwald

Updated Results From the CLEAR Trial: Outcomes of the Combination of…

09:12
AdventHealth

Update on the FDA Accelerated Approval of Enfortumab Vedotin + Pembr…

Feat. G. Sonpavde
10:11
University of Colorado Cancer Center

NCCN Guidelines Updates for the Treatment of Metastatic Urothelial C…

Feat. T. Flaig
09:54
Insights from 2024 ASCO® GU Annual Meeting

The Impact of Immunotherapy-Based Regimens in Primary Renal Tumors

Feat. R. McKay
05:59
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "EV-302/KEYNOTE-A39 Study of Enfortumab Ved…

Feat. T. Powles